Relevant bibliographies by topics / Cardiovascular disease – Prevention

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Cardiovascular disease – Prevention'

Author: Grafiati
Published: 4 June 2021
Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cardiovascular disease – Prevention.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cardiovascular disease – Prevention"

1

Aslam, Dr Imran, Yuldashev Soatboy Jiyanboyevich, and Abdurakhmanova Zamira Ergashboevna. "Prevention & Treatment Of Cardiovascular Diseases." American Journal of Medical Sciences and Pharmaceutical Research 03, no. 06 (June 10, 2021): 180–88. http://dx.doi.org/10.37547/tajmspr/volume03issue06-28.

Full text
Abstract:
Cardiovascular disease is a significant problem that humans have always faced, affecting thousands of people's lives and health and taking the lives of many people. Many medical institutions and researchers have regarded it as a significant problem in overcoming the cardiovascular disease.1 Much attention has been paid, so the prevention and treatment level in this area has also been rapidly improved. However, cardiovascular disease still cannot be prevented or treated fundamentally, and it is still a significant danger to human health. All people still hope for breakthrough results in cardiovascular disease.2 This article analyzes the prevention and treatment of cardiovascular diseases, and has obtained a series of practical and reliable conclusions.
APA, Harvard, Vancouver, ISO, and other styles
2

Pipe, Andrew. "Cardiovascular disease prevention." Current Opinion in Cardiology 33, no. 5 (September 2018): 498–99. http://dx.doi.org/10.1097/hco.0000000000000551.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Van Camp, G. "Cardiovascular disease prevention." Acta Clinica Belgica 69, no. 6 (August 31, 2014): 407–11. http://dx.doi.org/10.1179/2295333714y.0000000069.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Schargrodsky, Herman, María C. Escobar, and Edgardo Escobar. "Cardiovascular Disease Prevention." Circulation 98, no. 20 (November 17, 1998): 2103–4. http://dx.doi.org/10.1161/01.cir.98.20.2103.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Keevil, Jon G., James H. Stein, and Patrick E. McBride. "Cardiovascular disease prevention." Primary Care: Clinics in Office Practice 29, no. 3 (September 2002): 667–96. http://dx.doi.org/10.1016/s0095-4543(02)00012-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

B. Raghu. "Prevention of Cardiovascular Disease by Dietary n-3 Fatty Acid." International Journal of Integrative Medical Sciences 3, no. 9 (October 6, 2016): 404–11. http://dx.doi.org/10.16965/ijims.2016.124.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Shakhnoza, Iskandarova, and Amilova Asalya. "PREVENTION OF CORONARY HEART DISEASE." American Journal of Medical Sciences and Pharmaceutical Research 04, no. 04 (April 1, 2022): 19–21. http://dx.doi.org/10.37547/tajmspr/volume04issue04-05.

Full text
Abstract:
Primary prevention, based on healthy lifestyle habits that prevent the emergence of risk factors, is the preferred method of reducing cardiovascular risk. Reducing the prevalence of obesity is the most urgent task, and it is pleiotropic in that it affects blood pressure, lipid profile, glucose metabolism, inflammation, progression of atherothrombotic disease. Physical activity also improves several risk factors, with the added potential to lower heart rate.
APA, Harvard, Vancouver, ISO, and other styles
8

Lavie, Carl J., Ray W. Squires, and Gerald T. Gau. "Prevention of cardiovascular disease." Postgraduate Medicine 81, no. 5 (April 1987): 52–72. http://dx.doi.org/10.1080/00325481.1987.11699780.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Tenenbaum, Ariel, Mohammed Morad, and Joav Merrick. "Cardiovascular disease and prevention." International Journal of Adolescent Medicine and Health 26, no. 4 (November 1, 2014): 457–58. http://dx.doi.org/10.1515/ijamh-2014-0004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bloomgarden, Z. T. "Prevention of Cardiovascular Disease." Diabetes Care 30, no. 2 (January 26, 2007): 423–31. http://dx.doi.org/10.2337/dc07-zb02.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Cardiovascular disease – Prevention"

1

Baker, J. E. "Ethnicity and cardiovascular disease prevention." Thesis, University of Glasgow, 2015. http://theses.gla.ac.uk/6524/.

Full text
Abstract:
Background Public health interventions need to both improve health and reduce health inequalities, whilst using limited health care resources efficiently. Well-established ethnic differences in cardiovascular disease (CVD) raise the possibility that CVD prevention policies may not work equally well across ethnic groups. The aim of this thesis was to explore whether there are ethnic differences in the potential impact of two CVD prevention policy choices – the choice between mass and targeted screening for high cardiovascular risk, including the use of area deprivation measures to target screening, and the choice between population and high-risk approaches. Methods Cross-sectional data from the Health Survey for England 2003 and 2004 were used. Three sets of analyses were carried out – first, calculation of ethnic differences in the utility of area deprivation measures to identify individual socioeconomic deprivation; second, investigation of ethnic differences in the cost-effectiveness of mass and targeted screening for high cardiovascular risk; third, analysis of ethnic differences in the potential impact of population and high-risk approaches to CVD prevention. Results Area deprivation measures worked relatively effectively and efficiently at identifying individual socioeconomic deprivation in ethnic minority groups compared to the white group. In ethnic groups at high risk of CVD, cardiovascular risk screening programmes were a relatively cost-effective option, screening programmes targeted at deprived areas were particularly cost-effective, and population approaches were found to be an effective and equitable way of preventing CVD despite potential underestimation of their impact. Discussion This thesis found that ethnic minority groups in the UK are unlikely to be systematically disadvantaged by a range of CVD prevention policies that have been proposed, or implemented, for the general population. Additional CVD prevention policies, in particular those based on the population approach, should be implemented.
APA, Harvard, Vancouver, ISO, and other styles
2

Frauenberg, Sarah. "Aspirin Use for Primary Prevention of Cardiovascular Disease." Diss., North Dakota State University, 2019. https://hdl.handle.net/10365/29207.

Full text
Abstract:
Cardiovascular disease (CVD) is a major cause of morbidity and mortality in the United States and aspirin is a well-known medication strongly associated with CVD prevention. Aspirin has undeniable benefits in the role of secondary prevention of CVD, however, the benefits are ambiguous when associated with primary prevention. The decision to start aspirin for primary prevention becomes complicated due to aspirin?s effect on coagulation and the risk of gastric ulceration. The United States Preventive Services Task Force (USPSTF) has level B recommendations in place regarding the use of low-dose aspirin (81 mg) for primary prevention of CVD. In addition, the American Heart Association (AHA) and American College of Cardiology (ACC) developed a calculator in 2013 to determine a patient?s 10-year CVD risk. The guideline and CVD calculator offer healthcare providers an easy-to-navigate tool to determine proper patient use of aspirin. However, despite the USPSTF guideline, appropriate aspirin use remains suboptimal. Successful adoption of the 2016 USPSTF guideline on aspirin use for primary prevention of CVD by providers in two rural North Dakota communities was the goal of this practice improvement project. The project began with education to providers and staff at the rural clinics regarding the USPSTF guideline and the ACC/AHA calculator. Following the educational session, implementation of the USPSTF guideline occurred for three months. Evaluation was performed through the use of a post-implementation survey. Results of the project demonstrated increased knowledge and usage of the guideline and a positive viewpoint related to implementation of the guideline with the providers in both of the communities having plans to sustain use in future practice. Data were also collected at a health screening fair in one of the rural communities to validate whether patients were taking aspirin per USPSTF guideline. Data gathered from the fair concluded only 59% of patients (41 out of 70) were taking, or not taking, aspirin appropriately according to the USPSTF guideline. Conclusively, primary care providers would be well served by using the ACC/AHA calculator and 2016 USPSTF guideline with all patients 40-79 years of age to determine appropriate use of aspirin for primary prevention of CVD.
APA, Harvard, Vancouver, ISO, and other styles
3

Chu, Paula N. "Identifying High-Value Lifestyle Interventions for Cardiovascular Disease Prevention." Thesis, Harvard University, 2016. http://nrs.harvard.edu/urn-3:HUL.InstRepos:33493540.

Full text
Abstract:
This dissertation evaluates lifestyle strategies for the management of cardiovascular risk factors and prevention of cardiovascular disease (CVD). In Chapter 1, I systematically review and summarize the evidence of the effect of yoga, a popular mind-body practice, on cardiovascular disease and metabolic syndrome risk factors. I perform a narrative systematic review and a random-effects meta-analysis of randomized controlled trials (RCTs) of posture-based yoga practice. I find that yoga showed significant improvement in a variety of risk factors for CVD and metabolic syndrome, including body mass index, systolic blood pressure, and total cholesterol when compared to no or minimal intervention control groups. When compared to active exercise controls, yoga produced similar risk factor level reduction. Promising evidence supports yoga’s role in improving cardio-metabolic health. Findings are limited, however, by small trial sample sizes, heterogeneity, and moderate RCT quality. In Chapter 2, I evaluate the comparative effectiveness of four different lifestyle strategies for reducing 10-year CVD risk. I used published literature on risk factor reductions associated with group therapy for smoking cessation, Mediterranean diet, aerobic exercise (walking), and yoga together with the Pooled Cohort risk algorithms to calculate a personalized optimal strategy for risk reduction based on different risk profiles. I find that for smokers, successful smoking cessation is an optimal strategy for reducing risk whereas for non-smokers or for smokers who do not quit successfully, stress reduction through yoga produces the greatest risk reductions. In Chapter 3, I examine the cost-effectiveness of aerobic exercise and yoga compared to current medical practice for primary prevention of CVD in US adults. I use a subset of RCTs from Chapter 1, along with published literature on utilities, costs, and other parameters as inputs into a validated disease microsimulation model. I calculate the costs per quality-adjusted life year ($/QALY) of aerobic exercise and yoga with an exercise on prescription approach from the societal and healthcare perspective as well as if the activities were reimbursed. Results suggest that both interventions are not cost-effective using a threshold of $100,000/QALY due to high patient time costs in the societal perspective; when the activities are reimbursed and gains in quality of life are taken into account, then the activities can be cost-effective. Future research can explore patient preference and adherence and utility gains from physical activity.
Health Policy
APA, Harvard, Vancouver, ISO, and other styles
4

Collins, Dylan Raymond James. "Cardiovascular risk scoring for the prevention of cardiovascular disease in low-resource settings." Thesis, University of Oxford, 2017. http://ora.ox.ac.uk/objects/uuid:839de6e8-6cf6-4482-a352-201f4a595d56.

Full text
Abstract:
The aim of this thesis was to examine the use of total cardiovascular risk scoring for the prevention of cardiovascular disease (CVD) in low-resource settings. While risk scoring is popular in high-income countries, the overarching hypothesis was that it was sub-optimal for the prevention of CVD in low-resource settings. To achieve its aim, this thesis first synthesised evidence through a systematic review of systematic reviews on the impact of total CVD risk scoring on important patient outcomes. Second, it developed an R package to calculate World Health Organisation/International Society of Hypertension (WHO/ISH) CVD risk scores for all epidemiological subregions of the world. Third, using mixed methods and intensive fieldwork, it evaluated the practical implementation of WHO/ISH CVD risk scores in Médecins Sans Frontières clinics for Syrian refugees in Jordan. Lastly, it explored the potential to simplify CVD risk scores by replacing cholesterol information with body mass index using a contemporary CVD risk cohort from New Zealand. Overall, the findings showed that CVD risk scoring is sub-optimal for low-resource settings due to a lack of evidence of effectiveness, its difficulty to implement and test, and its potential to be simplified. Focus should be shifted towards conducting high quality randomised trials in low-resource settings, using simplified risk scores that can be completed in a single consultation, and further implementation studies in primary health care. With this in mind, cardiovascular risk scoring as a pivotal intervention for the prevention of CVD in low-resource settings should be judiciously compared to other alternatives, and if implemented, closely monitored for its impact on health outcomes.
APA, Harvard, Vancouver, ISO, and other styles
5

Wahman, Kerstin. "Cardiovascular disease prevention after spinal cord injury : a new challenge /." Stockholm, 2010. http://diss.kib.ki.se/2010/978-91-7409-936-2/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Shaw, I., BS Shaw, and GA Brown. "Influence of strength training on cardiac risk prevention in individuals without cardiovascular disease." African Journal for Physical, Health Education, Recreation and Dance, 2009. http://encore.tut.ac.za/iii/cpro/DigitalItemViewPage.external?sp=1001650.

Full text
Abstract:
Abstract It has widely been shown that exercise, particularly aerobic exercise, has extensive cardioprotective benefits and is an important tool in the prevention of coronary heart disease (CHD). The present investigation aimed to determine the multivariate impact of strength training, designed to prevent the development of CHD, on the Framingham Risk Assessment (FRA) score. Twenty-eight healthy untrained men with low CHD risk (mean age 28 years and 7 months) participated in an eight-week (3- d/wk) strength training programme. Self-administered smoking records, resting blood pressures, total cholesterol (TC), high-density lipoprotein cholesterol (HDLC), FRA scores and absolute 10-year risks for CHD were determined at the pre-test and post-test. After the eight-week period, no significant (p > 0.05) differences were found in number of cigarettes smoked daily, systolic blood pressure, TC, HDLC, FRA scores and absolute 10-year risks for CHD in both the strength-trained (n = 13) and non-exercising control (n = 15) groups. The data indicate that strength training did not reduce the risk of developing CHD and absolute 10-year risk for CHD as assessed by the FRA score.
APA, Harvard, Vancouver, ISO, and other styles
7

Maeng, Jae G., and Stephen A. Geraci. "Cardiovirology Clinic for Primary Prevention in HIV Patients: a Quality Improvement Assessment." Digital Commons @ East Tennessee State University, 2019. https://dc.etsu.edu/asrf/2019/schedule/191.

Full text
Abstract:
INTRODUCTION With effective highly active antiretroviral therapy (HAART), individuals with human immunodeficiency virus (HIV) infection now enjoy life expectancies approaching those of uninfected individuals. Prolonged longevity has increased the prevalence of non-communicable comorbidities within the HIV patient population. HIV is a known independent risk factor for atherosclerotic cardiovascular disease (ASCVD), imparting a 1.5-2 -fold higher incidence of major adverse cardiovascular events (MACE) on infected patients. Deaths from ASCVD have increased as a result, despite a decline in total mortality. The Center of Excellence for HIV/AIDS care established a Cardiovirology Clinic (CvC) focused on providing primary and secondary preventative cardiovascular care to its patients. To date, there are no known data on the efficacy of such an intervention. We sought to define the performance of this care model for primary prevention. METHODS Unique CvC patients (n=68) with a treatment delivery window between September 1, 2017 to August 31, 2018 were identified through billing records. All patients were receiving HAART as prescribed by their infectious disease provider. Those with established ASCVD (n=10) were excluded from analysis to limit the study to primary prevention patients. We collected data on ASCVD risk factors (family history of premature ASCVD and personal histories of smoking, diabetes, hypertension [with degree of control], dyslipidemia, drug and alcohol use, and exercise) from the electronic health record. Body-mass index and systolic (SBP) and diastolic (DBP) blood pressures were also collected. Laboratory values including CD4 cell count, HIV-1 viral load, proteinuria, glomerular filtration rate, total cholesterol (TC), triglycerides (TG), and high (HDL) and low density (LDL) lipoprotein were included in the data collection. Estimates of 5-year risk of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or need for major revascularization was calculated using the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) equations. Patient data were de-identified. Two-tailed, paired T-testing was performed for each factor comparing the initial and most recent follow-up values. Significance was defined as p value <0.05. RESULTS Using univariate analysis, reductions in D:A:D risk (relative 32.01%, absolute 1.49%, p CONCLUSION In this initial assessment, treated HIV patients appeared to enjoy meaningful reductions in MACE risk through the preventive care they received in this clinic, suggesting that CvCs could be a partial solution to the growing ASCVD morbidity and mortality among HIV-infected individuals. Limitations of this study include a small patient population (n=58) (limiting us to univariate analyses) and short duration of follow up (≤ 1 year). Data collection will continue annually for 4 additional years. With increasing subject numbers, multivariate analyses to determine if components of ASCVD risk reduction show interactions, and which factors, interactions and interventions impart the greatest risk reduction, will be performed in improve the quality of care.
APA, Harvard, Vancouver, ISO, and other styles
8

Song, Zhi 1970. "Antibiotic use in secondary prevention of cardiovascular disease : a pharmacoepidemiology study." Thesis, McGill University, 2005. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=98804.

Full text
Abstract:
Background. Several trials of antibiotic use for the secondary prevention of cardiovascular diseases have been performed but individual studies have produced conflicting and inconclusive results. Therefore, we performed a systematic review of published studies to synthesize the evidence. We also examined a large cohort of previously revascularized patients to assess if a small but meaningful benefit of antibiotic exists.
Research question. Whether antibiotic use, compared to non-use, can reduce future cardiovascular events in a population of previously revascularized patients.
Method. A meta-analysis and a nested case control study were both conducted to answer the research question. In the meta-analysis, PubMed and the Cochrane Central Registry of controlled trials were searched for studies published between January 1 1994 and December 31 2004 using keyword 'antibiotic use' and 'cardiovascular diseases'. 232 published papers were initially identified and 12 randomized trials meet our inclusion criteria. The data were combined using a random effects model. A sensitivity analysis with a fixed effects model was also performed. Our nested case control study was conducted on a cohort of all individuals ≥65 years of age who had a revascularization procedure from 1995 to 2000 and were registered in the Quebec universal health databases. The discharge date of each patient after revascularization was date of cohort entry. The primary endpoint was a composite of death, myocardial infraction and repeat revascularization. For each case, five controls were randomly selected and matched by date of cohort entry and age to the cases. Current users of antibiotics, those whose last prescription overlapped with the index date, were compared to individuals who were not exposed to antibiotics in the year preceding the event. Similarly the risk of recent (1-6 month) and past (6-12 months) antibiotic exposure was estimated. Odds ratios were calculated by using conditional logistic regression and adjusted for potential confounders.
Results. Our meta-analysis identified the 12 studies which randomized 10 231 patients to antibiotic treatment and 10 144 patients to control. The odds ratio for the composite event endpoint of death, myocardial infarction or revascularization was 0.92 (95CI%: 0.84-1.02). A similar result was found using a fixed effect model. No evidence for publication bias was found. Our nested case control study included 6 117 cases and 30 573 controls. The adjusted odds ratios of cardiac events for any current, recent and past antibiotic use were 1.12 [95%CI: 0.98-1.29], 1.21[95%CI: 1.07-1.28] and 1.31 [95%CI: 1.15-1.48], respectively.
Conclusion. No prevention association between antibiotic use and future cardiovascular events was shown either in the meta-analysis or our nested case control study. On the contrary, our nested case control study suggested increased risk long term following antibiotic exposure. One hypothesis to explain these results is that antibiotic exposure is a surrogate marker for a heightened inflammatory status that is associated with later cardiovascular risk.
APA, Harvard, Vancouver, ISO, and other styles
9

Veroni, Margherita. "The use of pharmacotherapies in the secondary prevention of coronary heart disease." University of Western Australia. School of Population Health, 2006. http://theses.library.uwa.edu.au/adt-WU2006.0029.

Full text
Abstract:
[Truncated abstract] Background: This thesis examines pharmacotherapy use in the secondary prevention of coronary heart disease. It includes antiplatelet agents, beta-blockers, statins and ACE inhibitors, all shown in landmark clinical trials and meta-analyses to reduce the risk of cardiac events in patients with known coronary disease. Underuse of effective preventive therapies represents a lost opportunity to reduce mortality and morbidity. Overseas studies have shown significant underuse of effective therapies at the time of hospital discharge following an acute event and later in ambulatory care. Australian data on prescribing practices following an acute coronary event and, ongoing use in ambulatory care are sparse. Aims: The aim of this thesis was to quantify the prescription of known effective therapies at the time of hospital discharge following an acute coronary event and ongoing use in ambulatory care. A secondary aim was to identify barriers to optimal secondary prevention thus providing an evidential basis to recommend change. Methods: This was an observational study of a cohort of post-MI patients admitted to a tertiary and affiliate hospital in Perth, Western Australia. The continuum of care from the treatment plan at discharge through to the treatment regimen and risk factor management 12 months post-MI was examined. The intermediate step, communication about the treatment plan with the patient and the primary health care provider was also examined. The study involved a review of hospital medical records and follow-up questionnaires to patients and their general practitioners at 3 and 12 months post-MI. All post-myocardial patients were included in the analysis of prescriptions at discharge. The follow-up study included patients 80 years and younger with no terminal conditions. Patient interviews at 3 months and interviews and focus groups with key hospital staff provided qualitative data to inform the quantitative data.
APA, Harvard, Vancouver, ISO, and other styles
10

Lamrock, Felicity. "The cost-effectiveness of novel biomarkers for the prevention of cardiovascular disease." Thesis, Queen's University Belfast, 2017. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.727416.

Full text
Abstract:
Cardiovascular disease is still highly prevalent worldwide, and it has been shown that novel biomarkers such as C-reactive protein have the potential ability to predict who is at risk for a cardiovascular event. Decision-analytic models can be used to assess whether different prevention strategies are not only effective but cost-effective. Within decision-analytic models, Markov models have often been used to quantify the movements of individuals between different health states over time, where movements can be influenced by characteristics of the individuals as well as the prevention strategies being applied. This thesis presents a new five-state Markov model to capture the flow of individuals across the different health states. Hazard ratios for conventional risk factors, as well as several novel biomarkers, are obtained for each of the permitted transitions between health states. Several approaches are used to obtain the hazard ratios, and a novel biomarker panel score created by linearly combining three novel biomarkers: C-reactive protein, NT-pro BNP, and Troponin I. Net reclassification indices are calculated to quantify the movements between risk categories as defined by European guidelines, with and without the use of one or more novel biomarkers for 10 year risk prediction of cardiovascular death. Transition probabilities between each of the health states are calculated for a number of different strategies, and combined with cost and utility information to create a cost-effectiveness model. Individuals deemed to be at intermediate risk of a cardiovascular event are assessed to address if the use of the novel biomarker panel score is cost-effective. A sensitivity analysis is performed to assess the robustness of the cost-effectiveness model by varying parameter inputs and performing a deterministic and probabilistic sensitivity analysis. A validation of the model is also performed to assess how closely the model predicts the number of deaths compared to those that occurred.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Cardiovascular disease – Prevention"

1

Wood, David. Cardiovascular disease prevention. London: Mosby, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Frank, Clifford R. Pediatric prevention of atherosclerotic cardiovascular disease. New York: Oxford University Press, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

S, Sever Peter, and Thom Simon, eds. Cardiovascular disease: Practical issues for prevention. St Albans: Caroline Black, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Martin, Seth S., ed. Precision Medicine in Cardiovascular Disease Prevention. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-75055-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Wilkinson, Michael J., Michael S. Garshick, and Pam R. Taub, eds. Prevention and Treatment of Cardiovascular Disease. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-78177-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Physical activity and cardiovascular disease prevention. Sudbury, Mass: Jones and Bartlett, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Cardiovascular disease and diet. Farmington Hills, Mich: Lucent Books, a part of Gale Cengage Learning, 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Xiao, Junjie, ed. Exercise for Cardiovascular Disease Prevention and Treatment. Singapore: Springer Singapore, 2017. http://dx.doi.org/10.1007/978-981-10-4304-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Xiao, Junjie, ed. Exercise for Cardiovascular Disease Prevention and Treatment. Singapore: Springer Singapore, 2017. http://dx.doi.org/10.1007/978-981-10-4307-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kåre, Berg, and Nora Audrey Hart 1936-, eds. Cardiovascular diseases: Genetics, epidemiology, and prevention. New York: Oxford University Press, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Cardiovascular disease – Prevention"

1

Hooker, Stephanie Ann. "Cardiovascular Disease Prevention." In Encyclopedia of Behavioral Medicine, 377–80. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-39903-0_1611.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hooker, Stephanie Ann. "Cardiovascular Disease Prevention." In Encyclopedia of Behavioral Medicine, 337–40. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4419-1005-9_1611.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Marin-Neto, José Antonio, Anis Rassi, Andréa Silvestre de Sousa, João Carlos Pinto Dias, and Anis Rassi. "Chagas Disease: A Neglected Disease." In Prevention of Cardiovascular Diseases, 159–82. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-22357-5_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Owen, Alice J., and Christopher M. Reid. "Prevention of Cardiovascular Disease." In Cardiovascular Clinical Trials, 345–77. Oxford, UK: Blackwell Publishing Ltd., 2012. http://dx.doi.org/10.1002/9781118399378.ch12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Shah, Maulik, and Reza Ardehali. "Prevention of Cardiovascular Disease." In A Practical Approach to Cardiovascular Medicine, 1–10. Oxford, UK: Wiley-Blackwell, 2011. http://dx.doi.org/10.1002/9781444393897.ch1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Barbir, Mahmoud, Fawzi Lazem, and Charles Ilsley. "Prevention of cardiovascular disease." In Developments in Cardiovascular Medicine, 495–517. Dordrecht: Springer Netherlands, 1996. http://dx.doi.org/10.1007/978-94-011-5406-2_35.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

de Melo Barbosa, Marcia, Maria do Carmo Pereira Nunes, and Regina Müller. "Rheumatic Heart Disease: A Neglected Heart Disease." In Prevention of Cardiovascular Diseases, 143–57. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-22357-5_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Claas, Steven A., Stella Aslibekyan, and Donna K. Arnett. "Genetics of Cardiovascular Disease." In Prevention of Cardiovascular Diseases, 117–27. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-22357-5_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Rippe, James M. "Obesity and Cardiovascular Disease." In Obesity Prevention and Treatment, 135–49. Boca Raton: CRC Press, 2021. http://dx.doi.org/10.1201/9781003099116-14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Raczynski, James M., Martha M. Phillips, Carol E. Cornell, M. Janice Gilliland, Bonnie Sanderson, and Vera Bittner. "Cardiovascular Diseases." In Handbook of Health Promotion and Disease Prevention, 231–59. Boston, MA: Springer US, 1999. http://dx.doi.org/10.1007/978-1-4615-4789-1_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Cardiovascular disease – Prevention"

1

Esina, Е. Y., A. A. Zuykova, N. V. Strachova, V. V. Lyutov, and V. N. Tsigan. "Unresolved Cardiovascular Disease Prevention Issues." In Proceedings of the International Conference on Health and Well-Being in Modern Society (ICHW 2019). Paris, France: Atlantis Press, 2019. http://dx.doi.org/10.2991/ichw-19.2019.24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Guillen, Sergio G., Pilar Sala, Joerg Habetha, Ralf Schmidt, and Maria-Teresa Arredondo. "Innovative Concepts for Prevention and Disease Management of Cardiovascular Diseases." In Conference Proceedings. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE, 2006. http://dx.doi.org/10.1109/iembs.2006.259449.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Guillen, Sergio G., Pilar Sala, Joerg Habetha, Ralf Schmidt, and Maria-Teresa Arredondo. "Innovative Concepts for Prevention and Disease Management of Cardiovascular Diseases." In Conference Proceedings. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE, 2006. http://dx.doi.org/10.1109/iembs.2006.4397420.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Yimsiriwattana, Worrasak, and Edwin Inciong. "Adapting a Western cardiovascular disease prevention program to local environments." In International Conference on Health, Safety and Environment in Oil and Gas Exploration and Production. Society of Petroleum Engineers, 2012. http://dx.doi.org/10.2118/157553-ms.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Narasimhan, Lakshmi, Di Wu, and Narinder Gill. "Meta-Analysis of Clinical Cardiovascular Data towards Evidential Reasoning for Cardiovascular Life Cycle Management." In InSITE 2007: Informing Science + IT Education Conference. Informing Science Institute, 2007. http://dx.doi.org/10.28945/3147.

Full text
Abstract:
The cardiovascular disease is one of the serious and life-threatening diseases in the developed world. One aspect of medical treatment is using drugs with blood pressure reducing or cholesterol lowering functions. Importantly, such treatment needs to be individually tailored and is significantly correlated to the particular conditions of individual patients. However, such pathologies and mechanisms are still only under investigation. Several novel and unique computational methods, called meta-analyses techniques, for formatting and analyzing a wide variety of cardiac datasets are discussed in this paper with the aim to building cardiovascular database and related patient life-cycle management services. In this paper we also present an overview of a second order inference engine underlying the meta-analyses, which yields evidenced-based reasoning that is more likely to better assist decision-making on the effectiveness of cardiovascular treatment than what is available currently. Furthermore, the software architecture and other details of such a medical informatics system tailored to cardiovascular disease are also described. Research and development work on this project yields itself to application to many other areas, such as disease control and prevention in Epidemiology, and dietics. The system can therefore make a profound impact to medical informatics.
APA, Harvard, Vancouver, ISO, and other styles
6

Zhanpeng Jin, Joseph Oresko, Shimeng Huang, and Allen C. Cheng. "HeartToGo: A Personalized medicine technology for cardiovascular disease prevention and detection." In 2009 IEEE/NIH Life Science Systems and Applications Workshop (LiSSA) Formerly known as LSSA and. IEEE, 2009. http://dx.doi.org/10.1109/lissa.2009.4906714.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Fhadil, S., P. Wright, M. Khuu, B. Hazelrigg, A. Jung, O. Ruthsatz, and S. Antoniou. "4CPS-025 Lipid modification therapy for primary prevention of cardiovascular disease." In 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.174.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Powell, C., A. Wyse, and M. Widdowson. "35 Aspirin: a snapshot of current practice in cardiovascular disease prevention." In Irish Cardiac Society Annual Scientific Meeting & AGM, October 6th – 8th 2022, Radisson Hotel, Little Island, Cork Ireland. BMJ Publishing Group Ltd and British Cardiovascular Society, 2022. http://dx.doi.org/10.1136/heartjnl-2022-ics.35.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Al-Omari, H., H. Cutting, and C. Thomson. "45 Improving cardiovascular disease (CVD) prevention in london; a co-ordinated approach." In Leaders in Healthcare Conference, Poster Abstracts, 4–6 November 2019, Birmingham, UK. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/leader-2019-fmlm.45.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Siswanto, Boby. "Problem Identification on Cardiovascular Disease Prevention using Artificial Intelligence: A Literature Review." In 2022 International Conference on Informatics, Multimedia, Cyber and Information System (ICIMCIS). IEEE, 2022. http://dx.doi.org/10.1109/icimcis56303.2022.10017552.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Cardiovascular disease – Prevention"

1

Huang, Hao, Hechen Zhu, and Ru Ya. Statin use in older people primary prevention on cardiovascular disease: an updated systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2021. http://dx.doi.org/10.37766/inplasy2021.12.0045.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Wei, Dongmei, Yang Sun, and Hankang Hen. Effects of Baduanjin exercise on cardiac rehabilitation after percutaneous coronary intervention: A protocol for systematic review and meta-analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2022. http://dx.doi.org/10.37766/inplasy2022.4.0080.

Full text
Abstract:
Review question / Objective: Can Baduanjin exercise improve the cardiac rehabilitation of patients with coronary artery disease after percutaneous coronary artery surgery? Condition being studied: Coronary heart disease (CHD), also known as coronary artery disease (CAD), is the single most common cause of death globally, with 7.4 million deaths in 2013, accounting for one-third of all deaths (WHO 2014). PCI has been shown to be effective in reducing mortality in patients with CHD. During follow-up, it has been shown that the benefits of PCI can be offset by the significant risks of coronary spasm, endothelial cell injury, recurrent ischemia, and even restenosis or thrombus. Numerous guidelines endorse the necessity for cardiac rehabilitation (CR), which is recommended for patients with chronic stable angina, acute coronary syndrome and for patients following PCI. Baduanjin have been widely practised in China for centuries, and as they are considered to be low risk interventions, their use for the prevention of cardiovascular disease is now becoming more widespread. The ability of Baduanjin to promote clinically meaningful influences in patients with CHD after PCI, however, still remains unclear.
APA, Harvard, Vancouver, ISO, and other styles
3

Zhao, Fangfang, Chunli Lu, Luying Chen, Yaxin Guo, Lijie Lu, Yuerong Jiang, Jianping Liu, and Keji Chen. Red yeast rice preparations for dyslipidemia: A protocol for an overview of systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2022. http://dx.doi.org/10.37766/inplasy2022.3.0032.

Full text
Abstract:
Review question / Objective: What is the quality of systematic reviews/meta-analysis of red yeast rice (RYR) preparations for dyslipidemia? What is the comparative benefit of red yeast rice preparations on dyslipidemia compared to other lipid-lowering drugs? Based on the current controversies in dyslipidemia guidelines and clinical practice, to explore the relative benefits of red yeast rice compared with other lipid-lowering drugs, we plan to perform an overview of existing SRs/MAs. Condition being studied: Red yeast rice (RYR) has been used as an alternative to statin therapy in treating patients with dyslipidemia, particularly in those considered to be statin intolerant due to statin-associated myalgia (SAM), and clinical studies suggest that RYR is well-tolerated, safe, and effective for cardiovascular disease (CVD) primary prevention. Several studies support the beneficial effect of RYR on blood lipid profiles. Dyslipidemia is a worldwide public health challenge because of its high prevalence, leading to significant economic and social burdens. Many systematic reviews (SRs) /meta-analysis (MAs) have been performed to prove the effects of RYR on dyslipidemia during the past several years. High-quality SRs/MAs can provide clinicians, patients, and other decision-makers with a reliable scientific basis. However, existing SRs/MAs showed varied and heterogeneous results.
APA, Harvard, Vancouver, ISO, and other styles
4

FEDOTKINA, S. A., O. V. MUZALEVA, and E. V. KHUGAEVA. RETROSPECTIVE ANALYSIS OF THE USE OF TELEMEDICINE TECHNOLOGIES FOR THE PREVENTION, DIAGNOSIS AND TREATMENT OF HYPERTENSION. Science and Innovation Center Publishing House, 2021. http://dx.doi.org/10.12731/978-0-615-67320-2-4-22.

Full text
Abstract:
Introduction. The economic losses associated with disability due to diseases of the circulatory system, as well as the costs of providing medical care to patients suffering from heart and vascular diseases, are increasing annually. The state preventive measures currently being carried out are of a delayed nature. The results of the medical examination of the population of the Russian Federation in recent years (2015-2019) indicate that the incidence of cardiovascular diseases, including hypertension, is at a fairly high level. In the middle of the last century, the Concept of risk factors for the development of chronic non-communicable diseases were formulated, in the structure of which cardiovascular diseases, including arterial hypertension, occupies one of the primary positions. The concept is based on the results of promising epidemiological studies, and, at present, is a methodological basis for planning and organizing primary prevention of cardiovascular diseases. The purpose of the study. Based on the analysis of literary sources (including foreign ones) containing experience in the use of telemedicine technologies, to assess their significance for the prevention, diagnosis and treatment of hypertension, as well as forecasting improvements in the quality of medical care when adapting to the use of clinical recommendations. Materials and methods. The article provides an analytical review of the use of modern telemedicine technologies in the prevention of hypertension. The results of the study and their discussion. The analysis of literary sources has shown that in the context of the progress of information and telecommunication technologies in the healthcare system, a fundamentally new direction has appeared in the organization and provision of medical care to the population - telemedicine, which will ensure the modern level of prevention, detection and treatment of chronic non-communicable diseases, and also determines positive medical, social and economic performance indicators. To date, updates in the legislative framework of the Russian Federation are aimed at ensuring that medical care with the use of telemedicine technologies is more widespread, taking into account the standards of medical care and clinical recommendations. Conclusion. Based on a review of literature sources, it has been established that the modern solution to the problem of improving the quality of medical care for patients, including those with hypertension, diseases is medical care using telemedicine technologies that prove their medical, social and economic effectiveness.
APA, Harvard, Vancouver, ISO, and other styles
5

Liu, Mengnan, Raoqiong Wang, Ziyi Li, Maryam Mazhar, Gang Luo, and Sijin Yang. Danshen decoction in the treatment of heart failure: a systematic review and meta-analysis protocol of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2022. http://dx.doi.org/10.37766/inplasy2022.7.0107.

Full text
Abstract:
Review question / Objective: HF (heart failure) is considered to be the clinical endpoint and the leading cause of death of CVD (cardiovascular diseases). With people's growing desire for a healthy and better life, TCM (traditional Chinese medicine) as an alternative in the prevention and treatment of HF is becoming more popular. The basic and clinical research related to TCM has also been widely concerned by the cardiovascular community of scientists/clinicians. In recent years, a large number of preclinical (in vivo/in vitro) experiments and clinical observation studies have proved the therapeutic efficacy of Danshen decoction in the treatment of HF. However, systematic evaluation and review of the clinical treatment of Danshen decoction is insufficient, leaving objective and quantitative evaluation indicators of Danshen decoction to be inadequate. Therefore, evidence-based studies are urgently needed to demonstrate its efficacy and safety.
APA, Harvard, Vancouver, ISO, and other styles
6

Best Practices for Cardiovascular Disease Prevention Programs. National Center for Chronic Disease Prevention and Health Promotion, November 2022. http://dx.doi.org/10.15620/cdc:122281.

Full text
Abstract:
The Best Practices Guide for CVD Prevention describes and summarizes scientific evidence behind 8 effective strategies for lowering high blood pressure and cholesterol levels that can be implemented in health care systems and that involve community-clinical links. The guide is a resource for state and local health departments, decision makers, public health professionals, and other stakeholders interested in using proven strategies to improve cardiovascular health.
APA, Harvard, Vancouver, ISO, and other styles
7

Best Practices for Cardiovascular Disease Prevention Programs. National Center for Chronic Disease Prevention and Health Promotion (U.S.)., November 2022. http://dx.doi.org/10.15620/cdc:122290.

Full text
Abstract:
The Best Practices Guide for CVD Prevention describes and summarizes scientific evidence behind 8 effective strategies for lowering high blood pressure and cholesterol levels that can be implemented in health care systems and that involve community-clinical links. The guide is a resource for state and local health departments, decision makers, public health professionals, and other stakeholders interested in using proven strategies to improve cardiovascular health.
APA, Harvard, Vancouver, ISO, and other styles
8

Cancer, Reproductive, Cardiovascular and Other Chronic Disease Prevention Program. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, July 2017. http://dx.doi.org/10.26616/nioshpub2017206.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Cancer, Reproductive, Cardiovascular and Other Chronic Disease Prevention Program. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, July 2018. http://dx.doi.org/10.26616/nioshpub2018158.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

NIOSH Cancer, Reproductive, Cardiovascular and Other Chronic Disease Prevention Program. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, September 2019. http://dx.doi.org/10.26616/nioshpub2019170.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Cardiovascular disease – Prevention' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography